MetaCap

Grace Therapeutics (GRCE) vs Stablecoin Development (SDEV)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Grace Therapeutics (GRCE) has outperformed Stablecoin Development (SDEV) over the past year, losing 46.4% versus a loss of 88.4%. Over five years, GRCE leads with a -79.3% price change compared with -100.0% for SDEV. Stablecoin Development is the larger company by market cap ($36.9 million vs $36.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GRCE-46.39%SDEV-88.37%
+2239%+1020%-199%
Nov 21, 20251 yearNov 20, 2026
GRCE-80.48%SDEV-99.98%
+20%-43%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GRCE versus SDEV key metrics
MetricGRCESDEV
Share price$1.71$0.50
Market cap$35.97M$36.90M
1-day change-0.58%-10.30%
YTD return-50.58%-98.23%
1-year return-46.39%-88.37%
5-year return-79.35%-99.98%
P/E ratio (TTM)—0.19
EPS (TTM)$-1.16$2.70
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-7.79M$-630.78M
52-week high$5.18$99.75
52-week low$1.64$0.467
Distance from 52-week high-66.99%-99.50%
Analyst consensusnone—
Avg. price target upside+243.27%—
Average volume119.27K16.98M
Shares outstanding21.04M73.80M
Employees52
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GRCE has outperformed SDEV by 42.0 percentage points over the past year.

About Grace Therapeutics

GRCE stock →

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About Stablecoin Development

SDEV stock →

Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

GRCE vs SDEV FAQ

Which is bigger, Grace Therapeutics or Stablecoin Development?

Stablecoin Development (SDEV) is larger, with a market capitalization of $36.90M compared with $35.97M for Grace Therapeutics (GRCE).

Which stock has performed better over the past year, GRCE or SDEV?

GRCE returned -46.39% over the past 12 months, compared with -88.37% for SDEV (price return, excluding dividends). Past performance does not predict future results.

Are Grace Therapeutics and Stablecoin Development in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons